{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:20:42Z","timestamp":1790436042871,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Spanish Ministry of Economy, Industry and Competitiveness, Enisa (Empresa Nacional de Innovaci\u00f3n, S.A.)"},{"name":"Soprea (Sociedad para la Promoci\u00f3n y Reconversi\u00f3n Econ\u00f3mica de Andaluc\u00eda, S.A.U.)"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.leukres.2018.11.006","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T12:04:44Z","timestamp":1542110684000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-4091","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"P\u00e9rez-Oteyza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimundo","family":"Garc\u00eda-Boyero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Jim\u00e9nez-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Vidriales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Lavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Tormo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Colorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Bergua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Hern\u00e1ndez-Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Gorrochategui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Primo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Villoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Moscard\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Troconiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Linares G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.11.006_bib0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.23404","article-title":"Acute myeloid leukemia: 2013 update on risk-stratification and management","volume":"88","author":"Estey","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/MOH.0b013e32835d821c","article-title":"The evolving molecular genetic landscape in acute myeloid leukaemia","volume":"20","author":"Sanders","year":"2013","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2014.07.002","article-title":"Emerging strategies for high-risk and relapsed\/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials","volume":"29","author":"Sasine","year":"2015","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2018.11.006_bib0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.11.006_bib0025","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.2004.05.065","article-title":"American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays","volume":"22","author":"Schrag","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1445-5994.2012.02868.x","article-title":"High-dose cytarabine (24 g\/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia","volume":"43","author":"Low","year":"2013","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.leukres.2018.11.006_bib0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clml.2013.11.006","article-title":"Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine","volume":"14","author":"Bennett","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2018.11.006_bib0040","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2018.11.006_bib0045","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0050","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1038\/psp.2013.71","article-title":"Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods","volume":"3","author":"Upton","year":"2014","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0055","unstructured":"S.L. Beal, L.B. Sheiner, A.J. Boeckmann, R.J. Bauer, NONMEM Users Guides. Icon Development Solutions, Ellicot City, Maryland, 1989\u20132001."},{"key":"10.1016\/j.leukres.2018.11.006_bib0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.leukres.2018.11.006_bib0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.leukres.2018.11.006_bib0070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.11.006_bib0075","series-title":"Generalized Additive Models. An Introduction with R. Chapman & Hall","author":"Wood","year":"2006"},{"key":"10.1016\/j.leukres.2018.11.006_bib0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0022-1759(96)00013-0","article-title":"Two-graph receiver operating characteristic (TG-ROC): update version supports optimisation of cut-off values that minimise overall misclassification costs","volume":"191","author":"Greiner","year":"1996","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.leukres.2018.11.006_bib0085","series-title":"Innovative Leukemia and Lymphoma Therapy","first-page":"23","article-title":"Individualized tumor response testing in leukemia and lymphoma","author":"Bosanquet","year":"2008"},{"key":"10.1016\/j.leukres.2018.11.006_bib0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3343\/kjlm.2007.27.2.89","article-title":"Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia","volume":"27","author":"Jun","year":"2007","journal-title":"Korean J. Lab. Med."},{"issue":"2001","key":"10.1016\/j.leukres.2018.11.006_bib0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1034\/j.1600-0609.2001.00361.x","article-title":"Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia","volume":"66","author":"Norgaard","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0100","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2018.11.006_bib0105","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1158\/1535-7163.MCT-13-0692","article-title":"BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia","volume":"12","author":"Pierceall","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2018.11.006_bib0110","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.2005.05402.x","article-title":"Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci","volume":"128","author":"Staib","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0115","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/sj.leu.2402305","article-title":"Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia","volume":"15","author":"Yamada","year":"2001","journal-title":"Leukemia."},{"key":"10.1016\/j.leukres.2018.11.006_bib0120","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.blre.2005.08.003","article-title":"Tumor microenvironment and drug resistance in hematologic malignancies","volume":"20","author":"Li","year":"2006","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2018.11.006_bib0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/ehm.11.30","article-title":"The bone marrow microenvironment and leukemia: biology and therapeutic targeting","volume":"4","author":"Sison","year":"2011","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11899-015-0253-6","article-title":"Role of microenvironment in resistance to therapy in AML","volume":"10","author":"Tabe","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2018.11.006_bib0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphar.2013.00028","article-title":"Mechanisms and insights into drug resistance in cancer","volume":"4","author":"Zahreddine","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0140","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0091270007302563","article-title":"Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia","volume":"47","author":"Quartino","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.leukres.2018.11.006_bib0145","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.11.006_bib0150","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1046\/j.1365-2141.1999.01629.x","article-title":"Management of relapsed acute myeloid leukaemia","volume":"106","author":"Webb","year":"1999","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618304673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618304673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:41:46Z","timestamp":1775266906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618304673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":30,"alternative-id":["S0145212618304673"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.11.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}